Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,012 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cytokine release syndrome following durvalumab and tremelimumab in advanced hepatocellular carcinoma: A case report with cytokine and damage-associated molecular pattern analysis.
Ozaki T, Yumita S, Ogasawara S, Fujiya M, Tsuchiya T, Yoshino R, Sawada M, Akatsuka T, Izai R, Miwa C, Yonemoto T, Fujimoto K, Unozawa H, Fujiwara K, Kojima R, Kanzaki H, Koroki K, Inoue M, Kobayashi K, Nakamura M, Kiyono S, Kanogawa N, Kondo T, Nakagawa R, Nakamoto S, Kato N. Ozaki T, et al. Among authors: kobayashi k. Hepatol Res. 2024 Jun 29. doi: 10.1111/hepr.14088. Online ahead of print. Hepatol Res. 2024. PMID: 38943555
Carbon-ion radiotherapy versus radiofrequency ablation as initial treatment for early-stage hepatocellular carcinoma.
Fujita N, Kanogawa N, Makishima H, Ogasawara S, Maruta S, Iino Y, Shiko Y, Kanzaki H, Koroki K, Kobayashi K, Kiyono S, Nakamura M, Kondo T, Nakamoto S, Chiba T, Wakatsuki M, Itobayashi E, Obu M, Koma Y, Azemoto R, Kawasaki Y, Kato J, Tsuji H, Kato N. Fujita N, et al. Among authors: kobayashi k. Hepatol Res. 2022 Dec;52(12):1060-1071. doi: 10.1111/hepr.13827. Epub 2022 Sep 3. Hepatol Res. 2022. PMID: 35951438
Switching to systemic therapy after locoregional treatment failure: Definition and best timing.
Ogasawara S, Ooka Y, Koroki K, Maruta S, Kanzaki H, Kanayama K, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Suzuki E, Nakamoto S, Tawada A, Chiba T, Arai M, Kato J, Kato N. Ogasawara S, et al. Among authors: kobayashi k. Clin Mol Hepatol. 2020 Apr;26(2):155-162. doi: 10.3350/cmh.2019.0021n. Epub 2020 Jan 15. Clin Mol Hepatol. 2020. PMID: 31937081 Free PMC article. Review.
Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepatocellular Carcinoma.
Maruta S, Ogasawara S, Ooka Y, Obu M, Inoue M, Itokawa N, Haga Y, Seki A, Okabe S, Azemoto R, Itobayashi E, Atsukawa M, Sugiura N, Mizumoto H, Koroki K, Kanayama K, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Suzuki E, Nakamoto S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato N. Maruta S, et al. Among authors: kobayashi k. Liver Cancer. 2020 Aug;9(4):382-396. doi: 10.1159/000507022. Epub 2020 May 5. Liver Cancer. 2020. PMID: 32999866 Free PMC article.
Analyses of Intermediate-Stage Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization prior to Designing Clinical Trials.
Koroki K, Ogasawara S, Ooka Y, Kanzaki H, Kanayama K, Maruta S, Maeda T, Yokoyama M, Wakamatsu T, Inoue M, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Suzuki E, Nakamoto S, Yasui S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato J, Kuboki S, Ohtsuka M, Miyazaki M, Yokosuka O, Kato N. Koroki K, et al. Among authors: kobayashi k. Liver Cancer. 2020 Sep;9(5):596-612. doi: 10.1159/000508809. Epub 2020 Jul 22. Liver Cancer. 2020. PMID: 33083283 Free PMC article.
The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma.
Kanzaki H, Chiba T, Ao J, Koroki K, Kanayama K, Maruta S, Maeda T, Kusakabe Y, Kobayashi K, Kanogawa N, Kiyono S, Nakamura M, Kondo T, Saito T, Nakagawa R, Ogasawara S, Suzuki E, Ooka Y, Muroyama R, Nakamoto S, Yasui S, Tawada A, Arai M, Kanda T, Maruyama H, Mimura N, Kato J, Zen Y, Ohtsuka M, Iwama A, Kato N. Kanzaki H, et al. Among authors: kobayashi k. Sci Rep. 2021 Mar 5;11(1):5303. doi: 10.1038/s41598-021-84117-9. Sci Rep. 2021. PMID: 33674622 Free PMC article.
Serum Angiopoietin 2 acts as a diagnostic and prognostic biomarker in hepatocellular carcinoma.
Ao J, Chiba T, Kanzaki H, Kanayama K, Shibata S, Kurosugi A, Iwanaga T, Kan M, Sakuma T, Qiang N, Ma Y, Kojima R, Kusakabe Y, Nakamura M, Kobayashi K, Kiyono S, Kanogawa N, Saito T, Nakagawa R, Kondo T, Ogasawara S, Suzuki E, Nakamoto S, Muroyama R, Tawada A, Kato J, Kanda T, Maruyama H, Kato N. Ao J, et al. Among authors: kobayashi k. J Cancer. 2021 Mar 5;12(9):2694-2701. doi: 10.7150/jca.56436. eCollection 2021. J Cancer. 2021. PMID: 33854629 Free PMC article.
Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma.
Koroki K, Kanogawa N, Maruta S, Ogasawara S, Iino Y, Obu M, Okubo T, Itokawa N, Maeda T, Inoue M, Haga Y, Seki A, Okabe S, Koma Y, Azemoto R, Atsukawa M, Itobayashi E, Ito K, Sugiura N, Mizumoto H, Unozawa H, Iwanaga T, Sakuma T, Fujita N, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Saito T, Kondo T, Suzuki E, Ooka Y, Nakamoto S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato J, Kato N. Koroki K, et al. Among authors: kobayashi k. Liver Cancer. 2021 Apr 20;10(5):473-484. doi: 10.1159/000515552. eCollection 2021 Sep. Liver Cancer. 2021. PMID: 34721509 Free PMC article.
12,012 results
You have reached the last available page of results. Please see the User Guide for more information.